Le Lézard
Classified in: Ebola virus, Health, Business
Subjects: ERN, ACC

Essity's Interim Report, Quarter 1, 2024


STOCKHOLM, April 25, 2024 /PRNewswire/ -- 

Quarter 1, 2024 - High profitability and strong cash flow

CEO'S COMMENTS

Innovation-driven growth

"Volume growth was positive for the quarter, except for the impact of restructuring measures implemented in Professional Hygiene and contracts exited in Incontinence Products Health Care. In Consumer Goods, Feminine Care gained market shares and Incontinence Products Retail continued to grow strongly.

Essity is in better shape than ever. The pace of innovation is high, which provides us with a good foundation for growth moving forward and to gain market shares.

By increasing investments in sales and marketing in our segments with the highest margins, the product mix remained positive. The mix this quarter was mainly driven by Professional Hygiene and Health & Medical. The pace of innovation is high, which provides us with a good foundation for growth moving forward and to gain market shares."

Higher margins

"Margins were higher for all business areas. We have had a good price discipline despite lower costs for raw materials and energy compared with one year ago. The gap between our sales prices and costs has thus increased. In addition, we achieved good cost savings for the quarter through continuous efficiency improvements, primarily in sourcing and material rationalizations."

Strong cash flow and a good financial position

"During the quarter, we received proceeds of approximately SEK 19bn from the sale of shares in Vinda. The transaction entailed a profit from divestment of approximately SEK 9bn. We also continued to generate strong cash flow in operations, providing us with a good financial position. Essity is in better shape than ever."

Magnus Groth, President and CEO

INVITATION TO PRESENTATION

President and CEO Magnus Groth and Executive Vice President and CFO Fredrik Rystedt will present the interim report at a live webcast and teleconference at 09:00 CET on April 25, 2024.

Link to the live presentation, which can also be viewed afterwards: https://essity.videosync.fi/2024-04-25

Contact information for conference call with the possibility to ask questions:
UK: +44 (0) 33 0551 02 00
USA: +1 786 697 35 01
SWE: +46 (0) 8 505 204 24

Please call in well in advance of the start of the presentation. Indicate: "Essity".

The presentation will also be broadcast live on LinkedIn.

For additional information, please contact:
Fredrik Rystedt, CFO and Executive Vice President Tel: +46 (0) 8 788 51 31
Sandra Åberg, Vice President Investor Relations Tel: +46 (0) 70 564 96 89
Per Lorentz, Vice President Corporate Communications Tel: +46 (0) 73 313 30 55

NB: This interim report has not been reviewed by the company's auditors. This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of Karl Stoltz, Media Relations Director, at 07:00 CET on April 25, 2024

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/essity/r/interim-report--quarter-1--2024,c3967445

The following files are available for download:

https://mb.cision.com/Main/15798/3967445/2758499.pdf

Essity Report ENG

 


These press releases may also interest you

at 11:30
WomenHeart: The National Coalition for Women with Heart Disease, in collaboration with Bayer, is proud to announce the launch of the Understanding Her Heart: Women and Cardiovascular Disease initiative. This groundbreaking partnership aims to bolster...

at 11:15
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the publication of results from SLIM LIVER (also known as A5371) in the Annals of Internal Medicine. "The Effect of Open-Label Semaglutide on...

at 11:15
"My husband uses supplemental oxygen, and he needed a way to prevent continual kinks in the line," said an inventor, from Greenville, S.C., "so I invented the No Kink. My design helps provide continuous air flow, and it could also help prevent...

at 11:00
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has experienced a year of achievements across its three Centres of Excellence?Oncology, Genomics, and Transplantation. KFSH&RC's Oncology Centre of Excellence continues to lead the fight...

at 11:00
"I wanted to create a new type of mosquito repellant that can be worn on any area of the body to deter bites and irritation," said an inventor, from Waterbury, Conn., "so I invented the BYE BYE. My design enables you to enjoy a backyard party,...

at 11:00
Serotonin Centers, the nation's fastest-growing anti-aging/longevity franchise, has announced plans to continue the buildout of the brand's West Coast roots, having finalized its latest development deal for a new center in San Diego. A San...



News published on and distributed by: